Markets:

Overview

News

Currencies

International

Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

25.18 +0.52 (+2.11%)

Streaming Delayed Price Updated: 3:41 PM EST, Feb 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday ↗

June 13, 2025

Via Benzinga

Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics ↗

June 13, 2025

Via Benzinga

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

June 12, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

June 10, 2025

Company to host webcast on Thursday, June 12 at 6:00 pm ET

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics ↗

February 28, 2025

Via Benzinga

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

June 06, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 08, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

May 05, 2025

Phase 2 study fully enrolled; data expected in 2H 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews ↗

January 29, 2025

Via Benzinga

What Analysts Are Saying About Celldex Therapeutics Stock ↗

December 20, 2024

Via Benzinga

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock ↗

November 20, 2024

Via Benzinga

Analyst Expectations For Celldex Therapeutics's Future ↗

April 28, 2025

Via Benzinga

This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

April 28, 2025

Via Benzinga

7 Analysts Have This To Say About Celldex Therapeutics ↗

March 20, 2025

Via Benzinga

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

March 20, 2025

Via Benzinga

Celldex Therapeutics to Present at Upcoming Investor Conferences

March 04, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Analyst Expectations For Celldex Therapeutics's Future ↗

October 28, 2024

Via Benzinga

A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics ↗

September 25, 2024

Via Benzinga

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

March 03, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

March 01, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

February 27, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

February 18, 2025

Via Benzinga

Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors ↗

January 08, 2025

Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.

Via Benzinga

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

December 19, 2024

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

November 20, 2024

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Therapeutics to Present at Upcoming Investor Conferences

November 11, 2024

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

October 26, 2024

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

October 25, 2024

From Celldex Therapeutics, Inc.

Via GlobeNewswire

This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

September 27, 2024

Via Benzinga

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

September 25, 2024

From Celldex Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.